| Regan S Gallaher, MD | |
|
2200 Ada Ave Ste 305, Conway, AR 72034-4986 | |
| (501) 932-0352 | |
| Not Available |
| Full Name | Regan S Gallaher |
|---|---|
| Gender | Male |
| Speciality | Neurosurgery |
| Experience | 31 Years |
| Location | 2200 Ada Ave Ste 305, Conway, Arkansas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1992721880 | NPI | - | NPPES |
| P00301757 | Other | AR | RR MCR |
| 5M327 | Other | AR | AR BC/BS |
| 149280001 | Medicaid | AR |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207T00000X | Neurological Surgery | E3374 (Arkansas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Conway Regional Health System | Conway, AR | Hospital |
| Ozark Health | Clinton, AR | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Conway Regional Medical Center Inc | 3173428414 | 127 |
News Archive
It could take a mere 30 seconds to spot signs of Alzheimer's disease in 40 year-olds in the near future say scientists who are developing a new diagnostic test. Usually Alzheimer's disease is detected much later in life after the symptoms begin to appear.
Kaiser Health News staff writer Jordan Rau, working in collaboration with The Washington Post, reports on Provo, Utah: "If there is any place that should have medical spending under control, this is it" (Rau, 5/18).
By loading fragile RNA into silicon nanoparticles, researchers from The Methodist Hospital and two other institutions found a new drug delivery system can reduce the size of ovarian tumors by as much as 83 percent - and stop tumor growth in chemotherapy-resistant ovarian cancer tissue.
Light Sciences Oncology, Inc. (LSO) today announced the treatment of the first patients in a Phase 2 clinical trial of its innovative targeted drug treatment Aptocine(TM) (talaporfin sodium) in Benign Prostatic Hyperplasia (BPH). The Phase 2 trial expands the Aptocine BPH development program on the basis of a Phase 1 study at escalating light doses. In the open-label Phase 2 trial, Aptocine is being tested for safety and efficacy in 40 patients with lower urinary tract symptoms (LUTS) due to BPH. Aptocine is also in two Phase 3 clinical trials for solid tumors in the liver as well as preclinical development for prostate cancer.
› Verified 2 days ago
| Entity Name | Jefferson Hospital Association Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1932157674 PECOS PAC ID: 8123927431 Enrollment ID: O20040106000512 |
News Archive
It could take a mere 30 seconds to spot signs of Alzheimer's disease in 40 year-olds in the near future say scientists who are developing a new diagnostic test. Usually Alzheimer's disease is detected much later in life after the symptoms begin to appear.
Kaiser Health News staff writer Jordan Rau, working in collaboration with The Washington Post, reports on Provo, Utah: "If there is any place that should have medical spending under control, this is it" (Rau, 5/18).
By loading fragile RNA into silicon nanoparticles, researchers from The Methodist Hospital and two other institutions found a new drug delivery system can reduce the size of ovarian tumors by as much as 83 percent - and stop tumor growth in chemotherapy-resistant ovarian cancer tissue.
Light Sciences Oncology, Inc. (LSO) today announced the treatment of the first patients in a Phase 2 clinical trial of its innovative targeted drug treatment Aptocine(TM) (talaporfin sodium) in Benign Prostatic Hyperplasia (BPH). The Phase 2 trial expands the Aptocine BPH development program on the basis of a Phase 1 study at escalating light doses. In the open-label Phase 2 trial, Aptocine is being tested for safety and efficacy in 40 patients with lower urinary tract symptoms (LUTS) due to BPH. Aptocine is also in two Phase 3 clinical trials for solid tumors in the liver as well as preclinical development for prostate cancer.
› Verified 2 days ago
| Entity Name | Conway Regional Medical Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1255879656 PECOS PAC ID: 3173428414 Enrollment ID: O20170403000499 |
News Archive
It could take a mere 30 seconds to spot signs of Alzheimer's disease in 40 year-olds in the near future say scientists who are developing a new diagnostic test. Usually Alzheimer's disease is detected much later in life after the symptoms begin to appear.
Kaiser Health News staff writer Jordan Rau, working in collaboration with The Washington Post, reports on Provo, Utah: "If there is any place that should have medical spending under control, this is it" (Rau, 5/18).
By loading fragile RNA into silicon nanoparticles, researchers from The Methodist Hospital and two other institutions found a new drug delivery system can reduce the size of ovarian tumors by as much as 83 percent - and stop tumor growth in chemotherapy-resistant ovarian cancer tissue.
Light Sciences Oncology, Inc. (LSO) today announced the treatment of the first patients in a Phase 2 clinical trial of its innovative targeted drug treatment Aptocine(TM) (talaporfin sodium) in Benign Prostatic Hyperplasia (BPH). The Phase 2 trial expands the Aptocine BPH development program on the basis of a Phase 1 study at escalating light doses. In the open-label Phase 2 trial, Aptocine is being tested for safety and efficacy in 40 patients with lower urinary tract symptoms (LUTS) due to BPH. Aptocine is also in two Phase 3 clinical trials for solid tumors in the liver as well as preclinical development for prostate cancer.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Regan S Gallaher, MD 2200 Ada Ave Ste 305, Conway, AR 72034-4986 Ph: (501) 932-0352 | Regan S Gallaher, MD 2200 Ada Ave Ste 305, Conway, AR 72034-4986 Ph: (501) 932-0352 |
News Archive
It could take a mere 30 seconds to spot signs of Alzheimer's disease in 40 year-olds in the near future say scientists who are developing a new diagnostic test. Usually Alzheimer's disease is detected much later in life after the symptoms begin to appear.
Kaiser Health News staff writer Jordan Rau, working in collaboration with The Washington Post, reports on Provo, Utah: "If there is any place that should have medical spending under control, this is it" (Rau, 5/18).
By loading fragile RNA into silicon nanoparticles, researchers from The Methodist Hospital and two other institutions found a new drug delivery system can reduce the size of ovarian tumors by as much as 83 percent - and stop tumor growth in chemotherapy-resistant ovarian cancer tissue.
Light Sciences Oncology, Inc. (LSO) today announced the treatment of the first patients in a Phase 2 clinical trial of its innovative targeted drug treatment Aptocine(TM) (talaporfin sodium) in Benign Prostatic Hyperplasia (BPH). The Phase 2 trial expands the Aptocine BPH development program on the basis of a Phase 1 study at escalating light doses. In the open-label Phase 2 trial, Aptocine is being tested for safety and efficacy in 40 patients with lower urinary tract symptoms (LUTS) due to BPH. Aptocine is also in two Phase 3 clinical trials for solid tumors in the liver as well as preclinical development for prostate cancer.
› Verified 2 days ago